CTA
GBT

Carillon Tower Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Carillon Tower Advisers’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-307,452
Closed -$15M – 484
2020
Q1 		$15M Hold
307,452
– – 0.15% 212
2019
Q4 		$24.4M Hold
307,452
– – 0.16% 220
2019
Q3 		$14.9M Hold
307,452
– – 0.1% 285
2019
Q2 		$16.2M Buy
+307,452
New +$17.7M 0.11% 278

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carillon Tower Advisers's GBT Position: Q2 2020 in Review

Carillon Tower Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2020, closing a stake of 307,452 shares — an estimated $15M sold.

Carillon Tower Advisers first reported a position in GBT in Q2 2019 and held it in 4 quarters. The position peaked at $24.4M in Q4 2019. 253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

  • Carillon Tower Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Carillon Tower Advisers sold 307,452 Global Blood Therapeutics, Inc. shares in Q2 2020, an estimated $15M.
  • Carillon Tower Advisers first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 4 quarters.
  • Carillon Tower Advisers's Global Blood Therapeutics, Inc. position peaked at $24.4M in Q4 2019.
  • 253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on Carillon Tower Advisers's 13F filing for Q2 2020, filed 12 Aug 2020.